sunitinib malate — United Healthcare

Initial criteria

• Diagnosis of renal cell carcinoma (RCC)
• AND one of the following:
• Disease has relapsed
• Disease is advanced
• OR both of the following:
• Used in adjuvant setting
• Patient has a high risk of recurrence following nephrectomy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Sutent therapy

Approval duration

12 months